Table 2.

Univariate and multivariate analysis of TMEM176A methylation status with RFS or OS in colorectal cancer patients.

	OS				RFS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR(95% CI)	P	HR(95% CI)	P	HR(95% CI)	P	HR(95% CI)	P
Age (<50 vs.≥50 y)	1.085(0.472–2.492)	0.848			1.102(0.480–2.531)	0.819
Gender (male vs. female)	1.023(0.506–2.067)	0.95			1.065(0.527–2.152)	0.861
Tumor location (proximal colon vs. distal colon or rectum)	1.187(0.779–1.809)	0.425			1.182(0.776–1.801)	0.435
Tumor size (<5 cm vs. ≥5 cm)	1.313(0.667–2.585)	0.43			1.336(0.679–2.630)	0.402
Differentiation (high or middle vs. low differentiation)	0.381(0.193–0.751)	0.005**	0.549(0.269–1.122)	0.100	0.384(0.194–0.758)	0.006**	0.554(0.273–1.124)	0.102
Pathologic T stage (T3–4 vs. T1–2)	1.735(0.611–4.929)	0.301			1.626(0.573–4.616)	0.361
Pathologic N stage (N1–2 vs. N0)	3.687(1.761–7.718)	0.001**	2.651(1.203–5.846)	0.016*	3.749(1.790–7.850)	0.000**	2.799(1.283–6.109)	0.010**
TMEM176A (hypermethylation and unmethyaltion)	2.646(1.265–5.536)	0.01**	2.160(1.021–4.568)	0.044*	2.503(1.197–5.236)	0.015*	2.014(0.953–4.256)	0.067
KRAS mutation (wild type vs. mutation)	1.010(0.481–2.122)	0.979			1.021(0.486–2.145)	0.957
BRAF mutation (wild type vs. mutation)	2.956(0.705–12.394)	0.138			2.359(0.563–9.885)	0.240
CIMP(−) and CIMP(+)	0.986(0.67–1.451)	0.943			0.97(0.659–1.429)	0.878

^*P<0.05.

^**P≤0.01.